CryoPort, Inc. (CYRX) Announces Q3 Loss but Exceeds Revenue Projections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Should l Buy TOI?
Source: NASDAQ.COM
Quarterly Performance: CryoPort, Inc. reported a quarterly loss of $0.18 per share, better than the expected loss of $0.23, but worse than a loss of $0.02 per share a year ago, marking a 21.74% earnings surprise.
Revenue Insights: The company generated revenues of $44.23 million, exceeding the Zacks Consensus Estimate by 8.32%, although this is a decline from $56.66 million in the same quarter last year.
Stock Outlook: CryoPort's stock has increased by 16.2% year-to-date, slightly underperforming the S&P 500's 16.5% gain, with a current Zacks Rank of #3 (Hold), indicating expected performance in line with the market.
Industry Context: The Medical Services industry, where CryoPort operates, is currently ranked in the bottom 43% of Zacks industries, which may impact the stock's performance, while another industry peer, The Oncology Institute, is set to report its results soon.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TOI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TOI
Wall Street analysts forecast TOI stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.540
Low
5.00
Averages
6.67
High
8.00
Current: 3.540
Low
5.00
Averages
6.67
High
8.00
About TOI
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Topicus, Lumine, and Constellation Shareholder Meetings Scheduled
- Meeting Schedule: The annual shareholder meetings for Topicus, Lumine Group, and Constellation Software are set for May 15, 2026, at 8:00, 8:15, and 8:30 AM respectively, utilizing a hybrid format to accommodate both in-person and virtual attendance.
- Registration Requirement: Attendees are required to register online by May 8, 2026, to assist in tracking in-person attendance, ensuring smooth proceedings, with registration links available on each company's website.
- Q&A Session: A joint Q&A session will follow the meetings at 9:00 AM, allowing shareholders to participate either in person or virtually, with the option to submit questions in advance to enhance engagement.
- Technical Support: Shareholders must ensure they have internet-connected devices to participate in virtual meetings, with detailed participation instructions and proxy appointment guidelines provided on the respective company websites to facilitate smooth attendance.
See More
The Oncology Institute to Participate in Healthcare Conference
- Executive Participation: The Oncology Institute's CEO Daniel Virnich and CFO Rob Carter will participate in the 25th Annual Needham Healthcare Conference on April 15, 2026, showcasing the company's leadership in oncology care.
- Virtual Conference Format: The event will be held virtually, featuring a fireside chat at 3:45 p.m. ET, aimed at sharing the company's latest developments and strategic insights with investors.
- Investor Relations Access: A webcast link will be available on the company's Investor Relations website, ensuring that investors can access the conference content in real-time, enhancing transparency and engagement.
- Company Overview: Founded in 2007, The Oncology Institute provides value-based cancer care to approximately 1.9 million patients, employing over 180 clinicians and operating more than 100 clinics, demonstrating significant market influence.
See More
Oncology Institute Reports First Profitable Quarter and Strong Growth in 2025
- First Profitability Milestone: The Oncology Institute (TOI) achieved positive adjusted EBITDA in Q4 2025, marking its first profitable quarter as a public company, with expectations to maintain positive EBITDA in 2026, showcasing the sustainability and profitability of its business model.
- Significant Revenue Growth: In 2025, TOI's total revenue increased approximately 28% year-over-year, surpassing $500 million for the first time, primarily driven by the initiation of nine new capitated contracts, adding 260,000 patients and further solidifying its market position.
- Strong Pharmacy Performance: TOI's pharmacy revenue grew by 49.6% in 2025, reaching $269 million, contributing nearly $50 million in gross profit, reflecting its importance in the integrated care model and the rising market demand.
- Strategic Expansion and Leadership Enhancement: TOI strengthened its leadership team in 2025 with the addition of a Chief Clinical Officer and Chief Administrative Officer, expected to drive further market expansion and growth strategy, particularly in the capitated model in Florida for greater success.
See More
The Oncology Institute Reports Significant Revenue Growth in 2025 Financial Results
- Significant Revenue Growth: In Q4 2025, The Oncology Institute reported revenue of $142 million, a 41.6% increase from $100.3 million in Q4 2024, indicating strong market demand for its healthcare services and enhancing financial stability.
- Gross Profit Improvement: The company's gross profit rose 55.2% to $22.7 million in Q4, compared to $15 million a year earlier, reflecting improved operational efficiency and cost control capabilities.
- Narrowed Net Loss: The net loss for Q4 2025 was reduced to $7.5 million, or $0.06 per share, down from $13.2 million and $0.14 per share in the prior year, demonstrating positive progress in profitability.
- Optimistic Future Outlook: The Oncology Institute expects 2026 revenue between $630 million and $650 million, with gross profit projected between $97 million and $107 million, as management reaffirms its goal of achieving positive full-year Adjusted EBITDA in 2026, indicating substantial growth potential ahead.
See More
The Oncology Institute Reports Strong Q4 Results, Shares Surge
- Earnings Beat: The Oncology Institute reported a Q4 loss of 6 cents per share, outperforming the analyst consensus estimate of a 9-cent loss, indicating improvements in cost management and operational efficiency, which boosts market confidence in its future profitability.
- Sales Growth: The company achieved quarterly sales of $141.957 million, exceeding the analyst consensus of $139.775 million, reflecting positive progress in market demand and product promotion, thereby strengthening its market position in oncology treatment.
- Stock Surge: Shares of The Oncology Institute jumped 14.7% to $3.01 in pre-market trading, demonstrating a positive investor reaction to the financial results, which may attract more investor interest in its future developments.
- Increased Market Confidence: The better-than-expected performance not only enhances investor confidence but may also prompt analysts to reassess the company's long-term growth potential, potentially influencing future stock price movements and market performance.
See More
The Oncology Institute Reports First Profitable Quarter in Q4 2025
- Profitability Milestone: The Oncology Institute (TOI) achieved its first profitable quarter from adjusted EBITDA in Q4 2025, marking a significant financial turnaround as a public company, with expectations for positive adjusted EBITDA throughout 2026 indicating improved financial health.
- Patient Management Expansion: TOI signed nine new capitated contracts in 2025, adding approximately 260,000 patient lives under management across California, Florida, and Nevada, which is expected to drive future revenue growth and strengthen its market position.
- Strong Revenue Growth: Total revenue for Q4 reached $142 million, a 41.6% year-over-year increase, with pharmacy revenue soaring by 71.1% to $81.4 million, reflecting robust performance in patient services and pharmacy operations, enhancing competitive advantage in the market.
- Strategic Investment and Innovation: TOI plans to launch a proprietary network portal in Q2 2026 to improve patient engagement and pharmacy adoption, while ramping up its partnership with Elevance, anticipating over 80% growth in capitated revenue for 2026, laying a foundation for sustainable future growth.
See More
Topicus, Lumine, and Constellation Shareholder Meetings Scheduled
- Meeting Schedule: The annual shareholder meetings for Topicus, Lumine Group, and Constellation Software are set for May 15, 2026, at 8:00, 8:15, and 8:30 AM respectively, utilizing a hybrid format to accommodate both in-person and virtual attendance.
- Registration Requirement: Attendees are required to register online by May 8, 2026, to assist in tracking in-person attendance, ensuring smooth proceedings, with registration links available on each company's website.
- Q&A Session: A joint Q&A session will follow the meetings at 9:00 AM, allowing shareholders to participate either in person or virtually, with the option to submit questions in advance to enhance engagement.
- Technical Support: Shareholders must ensure they have internet-connected devices to participate in virtual meetings, with detailed participation instructions and proxy appointment guidelines provided on the respective company websites to facilitate smooth attendance.
See More
The Oncology Institute to Participate in Healthcare Conference
- Executive Participation: The Oncology Institute's CEO Daniel Virnich and CFO Rob Carter will participate in the 25th Annual Needham Healthcare Conference on April 15, 2026, showcasing the company's leadership in oncology care.
- Virtual Conference Format: The event will be held virtually, featuring a fireside chat at 3:45 p.m. ET, aimed at sharing the company's latest developments and strategic insights with investors.
- Investor Relations Access: A webcast link will be available on the company's Investor Relations website, ensuring that investors can access the conference content in real-time, enhancing transparency and engagement.
- Company Overview: Founded in 2007, The Oncology Institute provides value-based cancer care to approximately 1.9 million patients, employing over 180 clinicians and operating more than 100 clinics, demonstrating significant market influence.
See More
Oncology Institute Reports First Profitable Quarter and Strong Growth in 2025
- First Profitability Milestone: The Oncology Institute (TOI) achieved positive adjusted EBITDA in Q4 2025, marking its first profitable quarter as a public company, with expectations to maintain positive EBITDA in 2026, showcasing the sustainability and profitability of its business model.
- Significant Revenue Growth: In 2025, TOI's total revenue increased approximately 28% year-over-year, surpassing $500 million for the first time, primarily driven by the initiation of nine new capitated contracts, adding 260,000 patients and further solidifying its market position.
- Strong Pharmacy Performance: TOI's pharmacy revenue grew by 49.6% in 2025, reaching $269 million, contributing nearly $50 million in gross profit, reflecting its importance in the integrated care model and the rising market demand.
- Strategic Expansion and Leadership Enhancement: TOI strengthened its leadership team in 2025 with the addition of a Chief Clinical Officer and Chief Administrative Officer, expected to drive further market expansion and growth strategy, particularly in the capitated model in Florida for greater success.
See More
The Oncology Institute Reports Significant Revenue Growth in 2025 Financial Results
- Significant Revenue Growth: In Q4 2025, The Oncology Institute reported revenue of $142 million, a 41.6% increase from $100.3 million in Q4 2024, indicating strong market demand for its healthcare services and enhancing financial stability.
- Gross Profit Improvement: The company's gross profit rose 55.2% to $22.7 million in Q4, compared to $15 million a year earlier, reflecting improved operational efficiency and cost control capabilities.
- Narrowed Net Loss: The net loss for Q4 2025 was reduced to $7.5 million, or $0.06 per share, down from $13.2 million and $0.14 per share in the prior year, demonstrating positive progress in profitability.
- Optimistic Future Outlook: The Oncology Institute expects 2026 revenue between $630 million and $650 million, with gross profit projected between $97 million and $107 million, as management reaffirms its goal of achieving positive full-year Adjusted EBITDA in 2026, indicating substantial growth potential ahead.
See More
The Oncology Institute Reports Strong Q4 Results, Shares Surge
- Earnings Beat: The Oncology Institute reported a Q4 loss of 6 cents per share, outperforming the analyst consensus estimate of a 9-cent loss, indicating improvements in cost management and operational efficiency, which boosts market confidence in its future profitability.
- Sales Growth: The company achieved quarterly sales of $141.957 million, exceeding the analyst consensus of $139.775 million, reflecting positive progress in market demand and product promotion, thereby strengthening its market position in oncology treatment.
- Stock Surge: Shares of The Oncology Institute jumped 14.7% to $3.01 in pre-market trading, demonstrating a positive investor reaction to the financial results, which may attract more investor interest in its future developments.
- Increased Market Confidence: The better-than-expected performance not only enhances investor confidence but may also prompt analysts to reassess the company's long-term growth potential, potentially influencing future stock price movements and market performance.
See More
The Oncology Institute Reports First Profitable Quarter in Q4 2025
- Profitability Milestone: The Oncology Institute (TOI) achieved its first profitable quarter from adjusted EBITDA in Q4 2025, marking a significant financial turnaround as a public company, with expectations for positive adjusted EBITDA throughout 2026 indicating improved financial health.
- Patient Management Expansion: TOI signed nine new capitated contracts in 2025, adding approximately 260,000 patient lives under management across California, Florida, and Nevada, which is expected to drive future revenue growth and strengthen its market position.
- Strong Revenue Growth: Total revenue for Q4 reached $142 million, a 41.6% year-over-year increase, with pharmacy revenue soaring by 71.1% to $81.4 million, reflecting robust performance in patient services and pharmacy operations, enhancing competitive advantage in the market.
- Strategic Investment and Innovation: TOI plans to launch a proprietary network portal in Q2 2026 to improve patient engagement and pharmacy adoption, while ramping up its partnership with Elevance, anticipating over 80% growth in capitated revenue for 2026, laying a foundation for sustainable future growth.
See More
